Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine (ATTAIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02915744
Recruitment Status : Recruiting
First Posted : September 27, 2016
Last Update Posted : September 23, 2019
Sponsor:
Information provided by (Responsible Party):
Nektar Therapeutics

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : March 2021